SCHEMBL10249095

SCHEMBL10249095

Cc1cnc2c(c1)nc(-c1ccncc1C(=O)O)n2C

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ KDM4C Q9H3R0 4/20 0.37
▸ KDM5A P29375 1/20 0.37
▸ KDM5B Q9UGL1 1/20 0.37
▸ PDE10A Q9Y233 2/20 0.37
▸ DHODH Q02127 6/20 0.36
▸ AKT1 P31749 2/20 0.36
▸ AKT2 P31751 2/20 0.36
▸ BRD4 O60885 1/20 0.36
▸ SIRT3 Q9NTG7 1/20 0.35
▸ TDP1 Q9NUW8 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ POLB P06746 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ MEN1 O00255 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ CCNC P24863 1/20 0.34
▸ CDK8 P49336 1/20 0.34
▸ HASPIN Q8TF76 1/20 0.34
▸ CDK19 Q9BWU1 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10252614 0.89 SIRT3 (0.47) PDE10AAKT1AKT2SIRT3TDP1
SCHEMBL10249325 0.87 CYP46A1 (0.41) PDE10AALDH1A1POLBSMN1; SMN2MEN1
SCHEMBL10249121 0.87 PFKFB3 (0.35) PDE10AAKT1AKT2BRD4SIRT3
SCHEMBL10249139 0.87 PFKFB3 (0.36) PDE10ASIRT3TDP1ALDH1A1POLB
SCHEMBL10249147 0.85 ALDH1A1 (0.41) PDE10AALDH1A1POLBSMN1; SMN2
SCHEMBL10284937 0.85 POLB (0.46) KDM4CPDE10ADHODHPOLBMEN1
SCHEMBL10249120 0.84 PDE10A (0.36) PDE10ATDP1ALDH1A1SMN1; SMN2CCNC
SCHEMBL10252639 0.84 PDE2A (0.39) PDE10ABRD4SMN1; SMN2
SCHEMBL10249245 0.83 POLB (0.35) PDE10AAKT1AKT2BRD4SIRT3
SCHEMBL10249307 0.82 PDE10A (0.38) PDE10AAKT1AKT2BRD4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461181-B2 Fused heterocyclic compound and use thereof SUMITOMO CHEMICAL COMPANY, LTD. (JP) 2013-06-11 — — US disclosed
US-8273764-B2 Fused heterocyclic compounds and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-09-25 — — US disclosed
US-20120178779-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED 2012-07-12 — — US disclosed
US-20120015975-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-01-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178779-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF C3AR1, C9, C5 KDM4C 2026/4885KDM5A 4177/4885KDM5B 4245/4885
US-20120015975-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF C3AR1, C9, C5 KDM4C 2026/4885KDM5A 4177/4885KDM5B 4245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback